Skip to main content
Top
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Research

Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4

Authors: Abdel Rahman N Zekri, Hanaa M Alam El-Din, Abeer A Bahnassy, Mohsen M Khaled, Ashraf Omar, Inas Fouad, Mahmoud El-Hefnewi, Fouad Thakeb, Mostafa El-Awady

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

Background

HCV is one of the major health problems in Egypt, where it is highly prevalent. Genotype 4 is the most common genotype of HCV and its response to treatment is still a controversy.

Methods

HCV genotype 4 quasispecies diversity within the 5' untranslated region (5'UTR) was studied in a series of 22 native Egyptian patients with chronic hepatitis C virus with no previous treatment who satisfied all NIH criteria for combined treatment of pegylated IFN and ribavirine and was correlated with the outcome of treatment. The study also included 7 control patients with no antiviral treatment. HCV sequencing was done using the TRUGENE HCV 5-NC genotyping kit.

Results

At the 48th week of treatment, 15 patients (68%) showed virological response. Whereas HCV-RNA was still detected in 7 patients (32%) in this period; of those, 6 experienced a partial virological response followed by viral breakthrough during treatment. Only one patient did not show any virological or chemical response. The four females included in this study were all responders. There was a significant correlation between the response rate and lower fibrosis (p = 0.026) as well as the total number of mutation spots (including all the insertions, deletions, transitions and transversions) (p = 0.007, p = 0.035).

Conclusion

Patients who responded to interferon treatment had statistically significant less number in both transitions (p = 0.007) and the genetic distances between the quasispecies (p = 0.035). So, viral genetic complexity and variability may play a role in the response to IFN treatment. The consensus alignment of all three groups revealed no characteristic pattern among the three groups. However, the G to A transitions at 160 was observed among non responders who need further study to confirm this observation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alter HJ, Seeff LB: Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000,20(1):17-35. 10.1055/s-2000-9505PubMedCrossRef Alter HJ, Seeff LB: Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000,20(1):17-35. 10.1055/s-2000-9505PubMedCrossRef
2.
go back to reference El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A: Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996,3(5):261-264.PubMedCrossRef El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A: Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996,3(5):261-264.PubMedCrossRef
3.
go back to reference Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M: Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004,25(12):1935-1938.PubMed Al-Traif I, Handoo FA, Al-Jumah A, Al-Nasser M: Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004,25(12):1935-1938.PubMed
4.
go back to reference Pawlotsky JM: Hepatitis C virus resistance to antiviral therapy. Hepatology 2000,32(5):889-896. 10.1053/jhep.2000.19150PubMedCrossRef Pawlotsky JM: Hepatitis C virus resistance to antiviral therapy. Hepatology 2000,32(5):889-896. 10.1053/jhep.2000.19150PubMedCrossRef
5.
go back to reference Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D: Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 1998,54(4):256-264. 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3PubMedCrossRef Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D: Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 1998,54(4):256-264. 10.1002/(SICI)1096-9071(199804)54:4<256::AID-JMV4>3.0.CO;2-3PubMedCrossRef
6.
go back to reference Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T: Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 1997,26(1):6-13. 10.1016/S0168-8278(97)80002-5PubMedCrossRef Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T: Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 1997,26(1):6-13. 10.1016/S0168-8278(97)80002-5PubMedCrossRef
7.
go back to reference Hoofnagle JH: Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994, 39: 241-275.PubMed Hoofnagle JH: Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994, 39: 241-275.PubMed
8.
go back to reference Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F: Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 2004,74(1):41-53. 10.1002/jmv.20144PubMedCrossRef Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F: Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 2004,74(1):41-53. 10.1002/jmv.20144PubMedCrossRef
9.
go back to reference Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS: The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol 1995,90(6):951-954.PubMed Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS: The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Am J Gastroenterol 1995,90(6):951-954.PubMed
10.
go back to reference Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F, Mancia G: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995,21(3):645-649. 10.1016/0270-9139(95)90512-XPubMedCrossRef Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F, Mancia G: Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995,21(3):645-649. 10.1016/0270-9139(95)90512-XPubMedCrossRef
11.
go back to reference Hoffmann RM, Berg T, Teuber G, Prummer O, Leifeld L, Jung MC, Spengler U, Zeuzem S, Hopf U, Pape GR: Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. Z Gastroenterol 1999,37(8):715-723.PubMed Hoffmann RM, Berg T, Teuber G, Prummer O, Leifeld L, Jung MC, Spengler U, Zeuzem S, Hopf U, Pape GR: Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. Z Gastroenterol 1999,37(8):715-723.PubMed
12.
go back to reference Nakajima S, Kuroki T, Shintani M, Kurai O, Takeda T, Nishiguchi S, Shiomi S, Seki S, Kobayashi K: Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatology 1990,12(6):1261-1265.PubMedCrossRef Nakajima S, Kuroki T, Shintani M, Kurai O, Takeda T, Nishiguchi S, Shiomi S, Seki S, Kobayashi K: Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatology 1990,12(6):1261-1265.PubMedCrossRef
13.
go back to reference Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH: Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002,99(5):3081-3086. 10.1073/pnas.052712599PubMedPubMedCentralCrossRef Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH: Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002,99(5):3081-3086. 10.1073/pnas.052712599PubMedPubMedCentralCrossRef
14.
go back to reference Zekri AR, Bahnassy AA, Shaarawy SM, Mansour OA, Maduar MA, Khaled HM, El-Ahmadi O: Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of Hepatocellular carcinoma. J Med Microbiol 2000, 49: 89-95.PubMedCrossRef Zekri AR, Bahnassy AA, Shaarawy SM, Mansour OA, Maduar MA, Khaled HM, El-Ahmadi O: Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of Hepatocellular carcinoma. J Med Microbiol 2000, 49: 89-95.PubMedCrossRef
15.
go back to reference Zekri A-RN, Alam El-Din HM, Bahnassy AA, El-Shehabi AMR, El-Leethy H, Omar S, Khaled HM: TRUGENE Sequencing Versus INNO-LiPA for Sub-Genotyping of HCV Genotype-4. J Med Virology 2005, 75: 412-420. 10.1002/jmv.20293CrossRef Zekri A-RN, Alam El-Din HM, Bahnassy AA, El-Shehabi AMR, El-Leethy H, Omar S, Khaled HM: TRUGENE Sequencing Versus INNO-LiPA for Sub-Genotyping of HCV Genotype-4. J Med Virology 2005, 75: 412-420. 10.1002/jmv.20293CrossRef
16.
go back to reference National Institutes of Health: NIH Consensus Development Conference Statement: Management of C 2002: A Preliminary Draft Statement, June 10–12, 2002. Bethesda, Maryland. NIH Consensus Development Program; 2002. National Institutes of Health: NIH Consensus Development Conference Statement: Management of C 2002: A Preliminary Draft Statement, June 10–12, 2002. Bethesda, Maryland. NIH Consensus Development Program; 2002.
17.
go back to reference Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989,244(4902):359-362. 10.1126/science.2523562PubMedCrossRef Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989,244(4902):359-362. 10.1126/science.2523562PubMedCrossRef
18.
go back to reference Zekri A, Bahnassy A, Khaled H, Mansour O, Attia MA: Comparative analysis of different PCR techniques for detection of HCV in hepatocellular carcinoma patients. Cancer J 1995, 8: 331-335. Zekri A, Bahnassy A, Khaled H, Mansour O, Attia MA: Comparative analysis of different PCR techniques for detection of HCV in hepatocellular carcinoma patients. Cancer J 1995, 8: 331-335.
19.
go back to reference Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22: 4673-4680. 10.1093/nar/22.22.4673PubMedPubMedCentralCrossRef Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22: 4673-4680. 10.1093/nar/22.22.4673PubMedPubMedCentralCrossRef
20.
go back to reference Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucl Acids Symp Ser 1999, 41: 95-98. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucl Acids Symp Ser 1999, 41: 95-98.
21.
go back to reference Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of IFN α2b plus ribavirin for 48 weeks or for 24 weeks versus IFN α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4PubMedCrossRef Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of IFN α2b plus ribavirin for 48 weeks or for 24 weeks versus IFN α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352: 1426-1432. 10.1016/S0140-6736(98)07124-4PubMedCrossRef
22.
go back to reference Manns M, McHutchison J, Gordon S, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5PubMedCrossRef Manns M, McHutchison J, Gordon S, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358: 958-965. 10.1016/S0140-6736(01)06102-5PubMedCrossRef
23.
go back to reference Fried MW, Shiffman ML, Reedy R, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: PegIFN-α2a plus ribavirin for treatment of chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975-982. 10.1056/NEJMoa020047PubMedCrossRef Fried MW, Shiffman ML, Reedy R, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: PegIFN-α2a plus ribavirin for treatment of chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975-982. 10.1056/NEJMoa020047PubMedCrossRef
24.
go back to reference Koshy A, Marcellin P, Martinot M, Madda JP: Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000,20(4):335-339. 10.1034/j.1600-0676.2000.020004335.xPubMedCrossRef Koshy A, Marcellin P, Martinot M, Madda JP: Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver 2000,20(4):335-339. 10.1034/j.1600-0676.2000.020004335.xPubMedCrossRef
25.
go back to reference Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M: Pegylated interferon-alpha- 2b- ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Viral hepatitis 2005,12(4):380-385. 10.1111/j.1365-2893.2005.00604.xCrossRef Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M: Pegylated interferon-alpha- 2b- ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. Viral hepatitis 2005,12(4):380-385. 10.1111/j.1365-2893.2005.00604.xCrossRef
26.
go back to reference Zekri AR, Abdel Haleem H, Esmat El-DinG, Bahnassy A, Alam El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS: Immunomodulators, sFas and Fas-L as potential non-invasive predictors of IFN treatment in patients with HCV genotype-4. Journal of Viral Hepatitis 2006. (Ahead of pubmed, Jan 3, 2007 article number doi:10.1111/j.1365-2893.2006.00832.x) Zekri AR, Abdel Haleem H, Esmat El-DinG, Bahnassy A, Alam El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS: Immunomodulators, sFas and Fas-L as potential non-invasive predictors of IFN treatment in patients with HCV genotype-4. Journal of Viral Hepatitis 2006. (Ahead of pubmed, Jan 3, 2007 article number doi:10.1111/j.1365-2893.2006.00832.x)
27.
go back to reference Alves AV, de Azevedo AP, Perin C, Ramos GZ, Brandao AB, de Mattos AA, de Almeida PR: Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil. Arg Gastroenterol 2003,40(4):227-232. Alves AV, de Azevedo AP, Perin C, Ramos GZ, Brandao AB, de Mattos AA, de Almeida PR: Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil. Arg Gastroenterol 2003,40(4):227-232.
28.
go back to reference Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, Lunghi G, Piperno A, Valsecchi C, Fiorelli G: Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997,9(5):497-503.PubMedCrossRef Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, Cesana B, Lunghi G, Piperno A, Valsecchi C, Fiorelli G: Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997,9(5):497-503.PubMedCrossRef
29.
go back to reference Garrido A, Lepe JA, Guerrero FJ, Palomo S: Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon. Enferm Infecc Microbiol Clin 2000,18(10):512-515.PubMed Garrido A, Lepe JA, Guerrero FJ, Palomo S: Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon. Enferm Infecc Microbiol Clin 2000,18(10):512-515.PubMed
30.
go back to reference Fallows G, Kaita K, Minuk G, Penner F, Smart G, Dawood M, Rosser B: Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients. Can J Gastroenterol 2000,14(Suppl B):30B-35B.PubMed Fallows G, Kaita K, Minuk G, Penner F, Smart G, Dawood M, Rosser B: Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients. Can J Gastroenterol 2000,14(Suppl B):30B-35B.PubMed
31.
go back to reference Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L: HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). J Hepatol 1996,25(5):583-590. 10.1016/S0168-8278(96)80224-8PubMedCrossRef Magrin S, Craxi A, Fabiano C, Marino L, Fiorentino G, Lo Iacono O, Volpes R, Di Marco V, Almasio P, Vaccaro A, Urdea MS, Wilber JC, Bonura C, Gianguzza F, Capursi V, Filiberti S, Stuyver L, Pagliaro L: HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy). J Hepatol 1996,25(5):583-590. 10.1016/S0168-8278(96)80224-8PubMedCrossRef
32.
go back to reference Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000,288(5464):339-344. 10.1126/science.288.5464.339PubMedCrossRef Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ: The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000,288(5464):339-344. 10.1126/science.288.5464.339PubMedCrossRef
33.
go back to reference Lyra AC, Fan X, Di Bisceglie AM: Molecular biology and clinical implicationof hepatitis C virus. Brazilian Journal of Medical and Biological Research 2004, 37: 691-695. 10.1590/S0100-879X2004000500010PubMedCrossRef Lyra AC, Fan X, Di Bisceglie AM: Molecular biology and clinical implicationof hepatitis C virus. Brazilian Journal of Medical and Biological Research 2004, 37: 691-695. 10.1590/S0100-879X2004000500010PubMedCrossRef
Metadata
Title
Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4
Authors
Abdel Rahman N Zekri
Hanaa M Alam El-Din
Abeer A Bahnassy
Mohsen M Khaled
Ashraf Omar
Inas Fouad
Mahmoud El-Hefnewi
Fouad Thakeb
Mostafa El-Awady
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-16

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.